2
Clinical Trials associated with GSK-232802A parallel-group, double-blind, randomized, placebo-controlled,active comparator, multicenter study to evaluate the efficacy,safety, tolerability and pharmacokinetics of two doses ofGSK232802 administered orally as monotherapy for 12 weeksin healthy postmenopausal women with moderate to extremelysevere vasomotor symptomsEstudio de grupos paralelos, aleatorizado, doble ciego, controlado con placebo y con comparador activo, multicéntrico, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de dos dosis de GSK232802 administrado oralmente en monoterapia durante 12 semanas a mujeres postmenopáusicas sanas con síntomas vasomotores de moderados a muy intensos. - CNA109586
Start Date17 Sep 2007 |
Sponsor / Collaborator- |
A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 administered orally as monotherapy for 12 weeks in healthy postmenopausal women with moderate to extremely severe vasomotor symptoms - CNA109586
100 Clinical Results associated with GSK-232802
100 Translational Medicine associated with GSK-232802
100 Patents (Medical) associated with GSK-232802
100 Deals associated with GSK-232802